Tremelimumab (anti-CTLA-4)

目录号：A2021         批次号: A202104

打印

Tremelimumab (Ticilimumab, CP-675,206) 是一种全人源单克隆抗体，可与活化 T 淋巴细胞表面的细胞毒性 T 淋巴细胞相关蛋白 4 (CTLA-4) 结合。

抗体信息

CAS号 745013-59-6
配制 PBS Buffer, PH 7.4
推荐同型对照 Human IgG2
来源 HEK293 Cells
储存条件
(自收到货起)		 Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles
除菌 0.2 μM filtered
纯度 99.87%
蛋白浓度 8.05mg/ml
内毒素 <1 EU/mg

Tremelimumab (anti-CTLA-4)在文献中得到引用

In situ and dynamic screening of extracellular vesicles as predictive biomarkers in immune-checkpoint inhibitor therapies [ Journal of Nanobiotechnology, 2025, 411] PubMed: 40457452.0
In situ and dynamic screening of extracellular vesicles as predictive biomarkers in immune-checkpoint inhibitor therapies [ J Nanobiotechnology, 2025, 23(1):411] PubMed: 40457452

禁止用于人体及治疗！